Witold Tadeusz Cholewiński

Dr. Witold Tadeusz Cholewiński


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2020 in British Journal of Radiology
Verified
Journal Article
Closed access
JKJoanna Kaźmierska
Joanna Kaźmierska
WCWitold Tadeusz Cholewiński
Witold Tadeusz Cholewiński
TPTomasz Piotrowski
Tomasz Piotrowski
ASAnna Sowinska
Anna Sowinska
BBBartosz Bak
Bartosz Bak
Julian MalickiJulian Malicki
Julian Malicki
Objective: The aim of the study was to assess the feasibility of multitracer positron emission tomography (PET) imaging before and during chemoradiation and to evaluate the predictive value of image-based factors for outcome in locally advanced head and neck cancers treated with chemoradiation. Methods: In the week prior to the treatment [18F]−2-flu-2-deoxy-D-glucose (FDG), [18F]−3'-flu-3'deoxythymidine (FLT) and [18F]-flumisonidazole (FMISO) imaging was performed. FLT scans were repeated at 14 and 28 Gy and FMISO at 36 Gy. Overall survival, disease-free survival and local control were correlated with subvolume parameters, and with tumour-to-muscle ratio for FMISO. For every tracer, total metabolic tumour volume was calculated. Results: 33 patients were included. No correlation was found between pre-treatment maximum standardised uptake value for FDG, FLT, FMISO and outcomes. Tumour volume measured on initial CT scans and initial FLT volume correlated with disease-free survivall (p = 0.007 and 0.04 respectively). FDG and FLT metabolic tumour volumes correlated significantly with local control (p = 0.005 and 0.02 respectively). In multivariate Cox analysis only individual initial TMRmax correlated with overall survival. Conclusion: PET/CT imaging is a promising tool. However, various aspects of image analysis need further clinical validation in larger multicentre study employing uniform imaging protocol and standardisation, especially for hypoxia tracer. Advances in knowledge: Monitoring of biological features of the tumour using multitracer PET modality seems to be a feasible option in daily clinical practice. Evaluation of hypoxic subvolumes is more patient dependent; thus, exploration of individual parameters of hypoxia is needed. tumour-to-muscle ratio seems to be the most promising so far.

14 February 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PCPaulina Cegla
Paulina Cegla
GCGeoffrey Currie
Geoffrey Currie
JWJoanna Patrycja Wroblewska
Joanna Patrycja Wroblewska
WCWitold Tadeusz Cholewiński
Witold Tadeusz Cholewiński
JKJoanna Kaźmierska
Joanna Kaźmierska
EMEwa Majchrzak
Ewa Majchrzak
The aim of this study is to assess the influence of semiquantitative PET-derived parameters as well as hematological parameters in overall survival in HNSCC patients using neural network analysis. Retrospective analysis was performed on 106 previously untreated HNSCC patients. Several PET-derived parameters (SUVmax, SUVmean, TotalSUV, MTV, TLG, TLRmax, TLRmean, TLRTLG, and HI) for primary tumor and lymph node with highest activity were assessed. Additionally, hematological parameters (LEU, LEU%, NEU, NEU%, MON, MON%, PLT, PLT%, NRL, and LMR) were also assessed. Patients were divided according to the diagnosis into the good and bad group. The data were evaluated using an artificial neural network (Neural Analyzer version 2.9.5) and conventional statistic. Statistically significant differences in PET-derived parameters in 5-year survival rate between group of patients with worse prognosis and good prognosis were shown in primary tumor SUVmax (10.0 vs. 7.7; p = 0.040), SUVmean (5.4 vs. 4.4; p = 0.047), MTV (23.2 vs. 14.5; p = 0.010), and TLG (155.0 vs. 87.5; p = 0.05), and mean liver TLG (27.8 vs. 30.4; p = 0.031), TLRmax (3.8 vs. 2.6; p = 0.019), TLRmean (2.8 vs. 1.9; p = 0.018), and in TLRTLG (5.6 vs. 2.3; p = 0.042). From hematological parameters, only LMR showed significant differences (2.5 vs. 3.2; p = 0.009). Final neural network showed that for ages above 60, primary tumors SUVmax, TotalSUV, MTV, TLG, TLRmax, and TLRmean over (9.7, 2255, 20.6, 145, 3.6, 2.6, respectively) are associated with worse survival. Our study shows that the neural network could serve as a supplement to PET-derived parameters and is helpful in finding prognostic parameters for overall survival in HNSCC.

28 November 2021 in Metabolites
Verified
Journal Article
Open access
PDF file
PCPaulina Cegla
Paulina Cegla
FHFrank Hofheinz
Frank Hofheinz
WCWitold Tadeusz Cholewiński
Witold Tadeusz Cholewiński
RCRafał Czepczyński
Rafał Czepczyński
AKAnna Kubiak
Anna Kubiak
EBEwa Burchardt
Ewa Burchardt
The aim of this study was to assess the usefulness of pretherapeutic primary tumor metabolic tumor volume (MTV) in the prognosis of radically treated cervical cancer patients. Retrospective, single-centre analysis was performed on a group of 508 cervical cancer patients. All patients underwent a pretreatment [18F]FDG PET/CT study for the assessment of the disease stage. Several PET-derived parameters—namely, maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), total lesion glycolysis (TLG) and MTV, as well as the clinical parameters, were analysed in terms of the overall survival (OS), event-free survival (EFS), locoregional control (LRC) and freedom from distant metastases (FFDM). Hyperthermia and brachytherapy were prognostic for EFS, OS, and LRC.FIGO stage > II showed a significant effect on EFS, OS, and FFDM. Moreover, hysterectomy was prognostic for OS and histology was prognostic for FFDM. From the PET-derived parameters only MTV of the primary tumor had a significant influence on OS (cutoff point: >12.7 mL, HR: 2.8, 1.75–4.48 95% CI, p < 0.001), LRC (cutoff point: >13.7 mL, HR 2.82, 1.42–5.61 95% CI, p = 0.003), EFS (cutoff point: >10.4 mL, HR: 2.57, 1.67–3.97 95% CI, p < 0.001) and FFDM (cutoff point: >10.4 mL, HR: 5.04, 1.82–13.99 95% CI, p = 0.002). Pretreatment MTV from the primary tumor is the only independent prognostic parameter in OS, LRC, EFS, and FFDM in radically treated cervical cancer patients and should be used in clinical practice in assessing prognosis in these patients.

16 April 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
EBEwa Burchardt
Ewa Burchardt
WBWojciech Burchardt
Wojciech Burchardt
PCPaulina Cegla
Paulina Cegla
AKAnna Kubiak
Anna Kubiak
ARAndrzej Roszak
Andrzej Roszak
WCWitold Tadeusz Cholewiński
Witold Tadeusz Cholewiński
Purpose: This study aims to determine whether semiquantitative parameters obtained from both the primary tumor and metastatic pelvic lymph nodes (PLN) diagnosed in fluoro-18-deoxy-glucose positron emission tomography (FDG-PET-CT) are associated with disease-free survival (DFS), local control (LC), distant metastasis-free survival (DMFS) and overall survival (OS) in patients with locally advanced squamous cervical cancer (LACC) and metastatic pelvic lymph nodes. Materials: Retrospective analysis was performed on 93 female patients with FIGO IIIC1. The median age was 53 years (27–75). The PET parameters both in the primary tumor and metastatic pelvic lymph nodes, including SUVmax, SUVmean, TLG, MTV, heterogeneity, along with clinical variables, before radical cisplatin-based radiochemotherapy (RCT) were analyzed. The p-values < 0.05 were considered statistically significant. Results: Median follow-up was 38 months (4.5–92.6). Three years and five years OS were 75% and 70% respectively. Patients with SUVmax above 12.6, SUVmean above 7.6 and with TLG in tumors >245.7 lived longer (p < 0.05). The higher SUVmax or SUVmean reduced increased DMFS (HR 0.3 95%CI 0.56–0.96 and 0.59 95%CI 0.37–0.93). The clinical factors and other FDG PET CT parameters were not found to be statistically relevant in terms of OS, DFS, DM and LC. Conclusions: This study is the first report showing that in LACC patient population with PLN involvement treated with definitive RCT, high SUVmean, SUVmax and TLG of the primary tumor in FDG-PET-CT were linked with longer OS. Lower SUVmean and SUVmax were linked with shorter DMFS. None of the clinical factors and the nodal FDG-PET-CT parameters influenced the outcome.

29 December 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
EBEwa Burchardt
Ewa Burchardt
ZWZaneta Warenczak-Florczak
Zaneta Warenczak-Florczak
PCPaulina Cegla
Paulina Cegla
APAdam Piotrowski
Adam Piotrowski
ZCZefiryn Cybulski
Zefiryn Cybulski
WCWitold Tadeusz Cholewiński
Witold Tadeusz Cholewiński
This study aims to investigate if vaginal bacteriology obtained prior to treatment influences the 3′-deoxy-3 18F-fluorothymidine (FLT) [18F]FLT and 2-deoxy-2-[18F]fluoro-d-glucose (2-[18F]FDG) [18F]FDG parameters in positron emission tomography (PET/CT) in cervical cancer (CC) patients. Methods: Retrospective analysis was performed on 39 women with locally advanced histologically confirmed cervical cancer who underwent dual tracer PET/CT examinations. The [18F]FLT and [18F]FDG PET parameters in the primary tumor, including SUVmax, SUVmean, MTV, heterogeneity, before radiotherapy (RT) were analyzed, depending on the bacteriology. The p-values < 0.05 were considered statistically significant. Results: In the vaginal and/or cervical smears, there were 27 (79.4%) positive results. In seven (20.6%) cases, no opportunistic pathogen growth was observed (No Bacteria Group). In positive bacteriology, eleven (32%) Gram-negative bacilli (Bacteria group 2) and fifteen (44%) Gram-positive bacteria (Bacteria group 1) were detected. Five patients with unknown results were excluded from the analysis. Data analysis shows a statistically significant difference between the SUVmax, and SUVmin values for three independent groups for the [18F]FLT. Conclusions: The lowest values of SUVmax and SUVmin for [18F]FLT are registered in Gram-negative bacteria, higher are in Gram-positive, and the absence of bacteria causes the highest [18F]FLT values.

24 August 2026 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
KKKatarzyna Klappa
Katarzyna Klappa
WCWitold Tadeusz Cholewiński
Witold Tadeusz Cholewiński
MKMikolaj Kuta
Mikolaj Kuta
JSJakub Sarapata
Jakub Sarapata
PCPaulina Cegla
Paulina Cegla
Penile metastasis from prostate adenocarcinoma is an exceptionally rare manifestation of advanced disease. We report the case of a 64-year-old man with biopsy-proven prostatic adenocarcinoma (cT3bN1M1, Gleason 4+4=8), diagnosed in 2020 with an initial PSA of 122.85 ng/mL. The most remarkable finding was intense, diffuse, and homogeneous PSMA uptake throughout the corpora cavernosa along the entire penile shaft (SUVmax=76.9). Histopathologic examination confirmed metastatic prostatic adenocarcinoma (Grade Group 3, Gleason 4+3=7), involving 100% of the sampled penile tissue. This case illustrates an unusual pattern of diffuse penile involvement, likely reflecting advanced hematogenous or retrograde venous dissemination rather than focal metastatic deposits. It underscores the importance of careful evaluation of the external genitalia on PSMA PET/CT and highlights that penile metastases may present as diffuse, highly PSMA-avid infiltration in advanced prostate cancer.